A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through ...
Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk ...
The CNPV program significantly reduces drug review times, necessitating operational shifts for sponsors to meet compressed ...
In Episode 30, John Androsavich, Benjamin Fryer, and John Wilkerson go behind the headlines. Behind the Headlines examines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback